|Systematic (IUPAC) name|
|Protein binding||60 to 70%|
|Half-life||6 to 10 days|
|Mol. mass||500.423 g/mol|
|(what is this?)|
Halofantrine is a drug used to treat malaria. Halofantrine's structure contains a substituted phenanthrene, and is related to the antimalarial drugs quinine and lumefantrine. Marketed as Halfan, halofantrine is never used to prevent malaria and its mode of action is unknown, although a crystallographic study showed that it binds to hematin in vitro, suggesting a possible mechanism of action. Halofantrine has also been shown to bind to plasmpesin, a haemoglobin degrading enzyme unique to the malarial parasites.
Halofantrine can cause abdominal pain, diarrhoea, vomiting, rash, headache, itching and elevated liver enzymes.
It can be associated with cardiotoxicity. The most dangerous side effect is cardiac arrhythmias: halofantrine causes significant QT prolongation, and this effect is seen even at standard doses. The drug should therefore not be given to patients with cardiac conduction defects and should not be combined with mefloquine. A survey from 2009 suggests that the drug is safe when correctly administered it
Other adverse reactions
Consumption of grapefruit combined with certain medications can cause serious side effects, even death. Halofantrine combined with this fruit or grapefruit juice is dangerous. The mechanism of action is inhibition of CYP3A4, which is necessary to metabolize the drug and eliminate it from the body. Without CYP3A4, levels of the drug will become toxic in the body.
The mechanism of action of halofantrine is unknown. The absorption of halofantrine is erratic, but is increased when taken with fatty food. Because of fears of toxicity due to increased halofantrine blood levels, halofantrine should be taken on an empty stomach.
Plasma levels peak at 16 hours and the half-life of the drug is about 4 days.
Halofantrine is only used to treat malaria. It is not used to prevent malaria (prophylaxis) because of the risk of toxicity and unreliable absorption.
Adult dose: Three doses of 500 mg six hours apart. Halofantrine should be taken on an empty stomach.
Manufacturing information and availability
- de Villiers KA, Marques HM, Egan TJ (2008). "The crystal structure of halofantrine-ferriprotoporphyrin IX and the mechanism of action of arylmethanol antimalarials". J. Inorg. Chem. 102 (8): 1660–7. doi:10.1016/j.jinorgbio.2008.04.001. PMID 18508124.
- Friedman R, Caflisch A (2009). "Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring". ChemMedChem 4 (8): 1317–26. doi:10.1002/cmdc.200900078. PMID 19472268.
- Nielson, Donald (2006). A Heritage of Innovation: SRI's First Half Century. Menlo Park, California: SRI International. pp. 10–3 – 10–5. ISBN 978-0974520810.
- Wesche DL, Schuster BG, Wang WX, Woosley RL (May 2000). "Mechanism of cardiotoxicity of halofantrine". Clin. Pharmacol. Ther. 67 (5): 521–9. doi:10.1067/mcp.2000.106127. PMID 10824631.
- Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC (2004). "Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine". Naunyn Schmiedebergs Arch. Pharmacol. 370 (6): 484–91. doi:10.1007/s00210-004-0995-5. PMID 15558243.
- Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F (2009). "Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base". Malaria J. 8: 289. doi:10.1186/1475-2875-8-289. PMC 2801676. PMID 20003315.
- Colwell, W. T.; Brown, V.; Christie, P.; Lange, J.; Reece, C.; Yamamoto, K.; Henry, D. W. (1972). "Antimalarial arylaminopropanols". Journal of Medicinal Chemistry 15 (7): 771–775. doi:10.1021/jm00277a018.